Researchers disclosed Sibiriline, a small molecule that simultaneously inhibits necroptosis and ferroptosis in preclinical models. The compound blocks key effectors in both cell-death pathways and reduced tissue injury in inflammatory and degenerative disease models reported by the discovery team. Authors position Sibiriline as a tool compound to probe overlapping death programs and as a candidate for indications where mixed necroptotic/ferroptotic injury contributes to pathology. Translational steps noted include target deconvolution, PK/PD optimization, and safety profiling before candidate selection for clinical studies.